The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic relevance of KRAS genotype and the prevalent C.35 G > a mutation in metastatic colorectal cancer (MCRC) patients fitting for intensive FIr-B/FOx triplet chemotherapy plus bevacizumab.
Gemma Bruera
No relevant relationships to disclose
Katia Cannita
No relevant relationships to disclose
Alessandra Tessitore
No relevant relationships to disclose
Alessio Cortellini
No relevant relationships to disclose
Jean Christophe Sabourin
No relevant relationships to disclose
Mario Tosi
No relevant relationships to disclose
Thierry Frébourg
No relevant relationships to disclose
Edoardo Alesse
No relevant relationships to disclose
Corrado Ficorella
No relevant relationships to disclose
Enrico Ricevuto
No relevant relationships to disclose